SUSRF:OTC-Surgical Science Sweden AB (publ) (USD)

COMMON STOCK | Health Information Services |

Last Closing

USD 12.25

Change

0.00 (0.00)%

Market Cap

USD 0.61B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Surgical Science Sweden AB (publ) develops and markets virtual reality simulators for evidence-based medical training in Europe, North and South America, Asia, and internationally. The company offers Angio Mentor simulator for endovascular training; BRONCH Express, a portable version of BRONCH mentor simulator; ARTHRO Mentor for arthroscopic surgery skills acquisition; BRONCH Mentor, a simulator for optimizing bronchoscopy training; GI Mentor, a simulator for GI Endoscopy; HYST Mentor for True-To-Life diagnostic and therapeutic hysteroscopy training; URO Mentor, a virtual reality simulator for endourology training; EndoSim, a realistic scope simulator; FlexVR, a flexible and portable training platform which is designed to teach basic and advanced skills for robotic surgery; and LAP Mentor provides a wide array of laparoscopic training cases. It also provides LapSim training system comprising LapSim Haptic simulator provides laparoscopic training; LapSim essence, a portable and ready-to-use VR simulator; and LapSim 360, which provides high-immersion virtual reality training experience; MentorLearn, an end-to-end educational platform that makes simulation course management; and LapSim ST, a state-of-the-art training system that prepares students for the operating room. In addition, the company offers PELVIC Mentor simulator provides anatomy and pelvic exam training; Perc Mentor suite for image-guided interventions; RobotiX Mentor for practice the motor and cognitive skills for surgeons; Simball Box, which combines with digitally collected metrics into a powerful training tool; Spine Mentor, a training simulator for minimal invasive spine surgery; TEE Express, designed to teach Trans-Esophageal Echocardiography procedure using a TEE probe; TraumaVR, an ultimate mix of manikin and VR simulation; and Ultrasound Mentor for ultrasound training with multiple medical specialties. Surgical Science AB was incorporated in 1997 and is headquartered in Gothenburg, Sweden.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-26 )

Largest Industry Peers for Health Information Services

Symbol Name Price(Change) Market Cap
PMCUF Pro Medicus Limited

-3.81 (-3.20%)

USD 12.25B
MTHRY M3 Inc

-0.02 (-0.29%)

USD 6.94B
SMSZF SMS Co. Ltd

N/A

USD 1.52B
PANHF Ping An Healthcare and Technol..

N/A

USD 1.43B
SMSSY SMS Co., Ltd.

-0.18 (-2.24%)

USD 1.33B
CRWRF Craneware plc

N/A

USD 1.07B
SFSVF Software Service, Inc.

N/A

USD 0.50B
VHIBF Vitalhub Corp

N/A

USD 0.34B
KSIOF kneat.com inc.

+0.01 (+0.29%)

USD 0.31B
COGZF Cogstate Limited

N/A

USD 0.11B

ETFs Containing SUSRF

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health Information Services) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 3.46% 62% D 54% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.46% 60% D- 52% F
Trailing 12 Months  
Capital Gain -11.23% 68% D+ 44% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -11.23% 66% D+ 43% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -7.20% 45% F 26% F
Dividend Return -7.20% 45% F 24% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 24.54% 92% A 80% B-
Risk Adjusted Return -29.35% 33% F 21% F
Market Capitalization 0.61B 91% A- 69% C-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector